TrialOrphanet journal of rare diseases2026

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.

Myrl Holida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.